Program
gatuzosiran
A development code. Also written as “GSK4532990”.
In GlaxoSmithKline's pipeline, HSD17B13 RNA interference
. Its studies are mostly in Non-alcoholic Fatty Liver Disease · Liver Diseases, Alcoholic, led by GlaxoSmithKline.
Furthest: phase 2, since Oct 13, 20223 company-led studies, 1 open or runningNext primary completion: Nov 26, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 31 open or running | phase 2since Oct 13, 2022 | Oct 13, 2022 | Nov 26, 2027phase 2 · NCT06613698 |
- Named in GlaxoSmithKline’s own pipeline as
gatuzosiran GSK4532990
, phase 2, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 13, 2022First study: phase 2 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT05583344 · 284 enrolled · United States, Argentina, Australia and more
- Oct 23, 2023Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT06104319 · 61 enrolled · United States
- Sep 23, 2024Phase 2 study in Liver Diseases, AlcoholicNCT06613698 · 350 planned · United States, Argentina, Australia and more
Ahead
- Nov 26, 2027Primary completion: phase 2 study in Liver Diseases, AlcoholicNCT06613698
TargetBeta
“HSD17B13 RNA interference”the company's pipeline, read by Claude · source
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06613698Liver Diseases, Alcoholic · United States, Argentina, Australia and more | 2 | Recruiting | Nov 26, 2027 | 350 |
| NCT06104319Non-alcoholic Fatty Liver Disease · United States | 2 | Completed | Sep 23, 2025 | 61 |
| NCT05583344Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 2 | Completed | Jan 31, 2026 | 284 |
How it is read
Names in the registry
- “GSK4532990”, 3 entries
Codes read as this program: GSK4532990.
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 2 studies
- Liver Diseases, Alcoholic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.